Angiotensin-converting enzyme (ACE) inhibitors were found to be independently associated with reducing all-cause mortality in ...

The free hormone hypothesis: Correlation of decreases in PSA with free testosterone rather than total testosterone in men with advanced prostate cancer treated with GTx-758. Use of supportive measures ...

Angiotensin-converting enzyme (ACE) inhibitors are the mainstay of therapy for patients with systemic sclerosis in scleroderma renal crisis, however mortality remains high even in the post-ACE ...

ACE inhibitor use was associated with reduced all cause mortality in idiopathic pulmonary fibrosis in a matched real world ...

Treatment with an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker and sodium-glucose cotransporter-2 (SGLT2) inhibitor combination demonstrated better outcomes in kidney ...

Medically reviewed by Christopher Lee, MD Key Takeaways ACE inhibitors are used to treat high blood pressure and ...

Real-world EHR data suggest ACE inhibitor use is independently associated with lower all-cause mortality in idiopathic pulmonary fibrosis, while no similar survival association was observed in COPD.

Angiotensin converting enzyme (ACE) inhibitors, a type of blood pressure medication, are usually well tolerated, but one of their rare side effects is angioedema. Angiotensin converting enzyme (ACE) ...

Patients with left ventricular systolic dysfunction (LVSD) or heart failure (HF) are known to benefit from angiotensin-converting-enzyme (ACE) inhibitors, but three large, randomized trials testing ...

A new large-scale real-world study has found that the use of angiotensin-converting enzyme (ACE) inhibitors may be associated with improved survival in patients with idiopathic pulmonary fibrosis (IPF ...

Close-up of senior black woman sorting weekly medication. Member of a black middle class America family. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the ...

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without angiotensin-converting enzyme inhibitor use started within 5 years before ...